Literature DB >> 19247304

Molecular targets for cancer chemoprevention.

William N William1, John V Heymach, Edward S Kim, Scott M Lippman.   

Abstract

Vaccines targeting infections with hepatitis B virus, a risk factor for hepatocellular cancer, and human papillomavirus, a risk factor for cervical cancer, are considered major clinical cancer chemoprevention successes. Molecularly targeted agents can prevent breast cancer (raloxifene and tamoxifen), colorectal adenomas (celecoxib), and prostate cancer (finasteride). Nevertheless, the broad translation of chemoprevention to the clinic is not yet a reality. Continuing research of molecular targets promises to expand the reach of chemoprevention and to personalize it as well.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19247304     DOI: 10.1038/nrd2663

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  124 in total

1.  Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

Authors:  Daphne W Bell; Ira Gore; Ross A Okimoto; Nadia Godin-Heymann; Raffaella Sordella; Roseann Mulloy; Sreenath V Sharma; Brian W Brannigan; Gayatry Mohapatra; Jeff Settleman; Daniel A Haber
Journal:  Nat Genet       Date:  2005-10-30       Impact factor: 38.330

2.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

Review 3.  Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.

Authors:  Gary J Kelloff; Scott M Lippman; Andrew J Dannenberg; Caroline C Sigman; Homer L Pearce; Brian J Reid; Eva Szabo; V Craig Jordan; Margaret R Spitz; Gordon B Mills; Vali A Papadimitrakopoulou; Reuben Lotan; Bharat B Aggarwal; Robert S Bresalier; Jeri Kim; Banu Arun; Karen H Lu; Melanie E Thomas; Helen E Rhodes; Molly A Brewer; Michele Follen; Dong M Shin; Howard L Parnes; Jill M Siegfried; Alison A Evans; William J Blot; Wong-Ho Chow; Patricia L Blount; Carlo C Maley; Kenneth K Wang; Stephen Lam; J Jack Lee; Steven M Dubinett; Paul F Engstrom; Frank L Meyskens; Joyce O'Shaughnessy; Ernest T Hawk; Bernard Levin; William G Nelson; Waun Ki Hong
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

4.  Combination chemoprevention of cancer.

Authors:  M B Sporn
Journal:  Nature       Date:  1980-09-11       Impact factor: 49.962

5.  Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.

Authors:  Trevor J Powles; Sue Ashley; Alwynne Tidy; Ian E Smith; Mitch Dowsett
Journal:  J Natl Cancer Inst       Date:  2007-02-21       Impact factor: 13.506

6.  First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.

Authors:  J Cuzick; J Forbes; R Edwards; M Baum; S Cawthorn; A Coates; A Hamed; A Howell; T Powles
Journal:  Lancet       Date:  2002-09-14       Impact factor: 79.321

7.  Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis.

Authors:  S M Lippman; J G Batsakis; B B Toth; R S Weber; J J Lee; J W Martin; G L Hays; H Goepfert; W K Hong
Journal:  N Engl J Med       Date:  1993-01-07       Impact factor: 91.245

8.  TSC2 regulates VEGF through mTOR-dependent and -independent pathways.

Authors:  James B Brugarolas; Francisca Vazquez; Archana Reddy; William R Sellers; William G Kaelin
Journal:  Cancer Cell       Date:  2003-08       Impact factor: 31.743

9.  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study.

Authors:  U Veronesi; P Maisonneuve; A Costa; V Sacchini; C Maltoni; C Robertson; N Rotmensz; P Boyle
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321

Review 10.  The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.

Authors:  Silvana Martino; Joseph Costantino; Michelle McNabb; John Mershon; Katherine Bryant; Trevor Powles; Roberta J Secrest
Journal:  Oncologist       Date:  2004
View more
  49 in total

1.  Integrating molecular docking, DFT and CoMFA/CoMSIA approaches for a series of naphthoquinone fused cyclic α-aminophosphonates that act as novel topoisomerase II inhibitors.

Authors:  Yi Ma; Jian-Guo Wang; Bin Wang; Zheng-Ming Li
Journal:  J Mol Model       Date:  2010-11-25       Impact factor: 1.810

2.  A black raspberry extract inhibits proliferation and regulates apoptosis in cervical cancer cells.

Authors:  Zhaoxia Zhang; Thomas J Knobloch; Leigh G Seamon; Gary D Stoner; David E Cohn; Electra D Paskett; Jeffrey M Fowler; Christopher M Weghorst
Journal:  Gynecol Oncol       Date:  2011-08-09       Impact factor: 5.482

Review 3.  Diet and prostate cancer: mechanisms of action and implications for chemoprevention.

Authors:  Vasundara Venkateswaran; Laurence H Klotz
Journal:  Nat Rev Urol       Date:  2010-07-20       Impact factor: 14.432

4.  Identification of putative immunologic targets for colon cancer prevention based on conserved gene upregulation from preinvasive to malignant lesions.

Authors:  Elizabeth K Broussard; Rachel Kim; Jesse C Wiley; Juan Pablo Marquez; James E Annis; David Pritchard; Mary L Disis
Journal:  Cancer Prev Res (Phila)       Date:  2013-05-16

5.  Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16.

Authors:  Craig D Woodworth; Laura P Diefendorf; David F Jette; Abdulmajid Mohammed; Michael A Moses; Sylvia A Searleman; Dan A Stevens; Katelynn M Wilton; Sumona Mondal
Journal:  Virology       Date:  2011-10-05       Impact factor: 3.616

6.  Diet and esophageal disease.

Authors:  Sanford M Dawsey; Renato B Fagundes; Brian C Jacobson; Laura A Kresty; Susan R Mallery; Shirley Paski; Piet A van den Brandt
Journal:  Ann N Y Acad Sci       Date:  2014-09       Impact factor: 5.691

7.  Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.

Authors:  Dong M Shin; Hongzheng Zhang; Nabil F Saba; Amy Y Chen; Sreenivas Nannapaneni; A R M Ruhul Amin; Susan Müller; Melinda Lewis; Gabriel Sica; Scott Kono; Johann C Brandes; William J Grist; Rachel Moreno-Williams; Jonathan J Beitler; Sufi M Thomas; Zhengjia Chen; Hyung Ju C Shin; Jennifer R Grandis; Fadlo R Khuri; Zhuo Georgia Chen
Journal:  Clin Cancer Res       Date:  2013-02-19       Impact factor: 12.531

Review 8.  Molecular cancer prevention: Current status and future directions.

Authors:  Karen Colbert Maresso; Kenneth Y Tsai; Powel H Brown; Eva Szabo; Scott Lippman; Ernest T Hawk
Journal:  CA Cancer J Clin       Date:  2015-08-18       Impact factor: 508.702

Review 9.  Future directions in cancer prevention.

Authors:  Asad Umar; Barbara K Dunn; Peter Greenwald
Journal:  Nat Rev Cancer       Date:  2012-11-15       Impact factor: 60.716

10.  Introduction: Cancer chemoprevention and its context.

Authors:  Barbara K Dunn; Asad Umar; Ellen Richmond
Journal:  Semin Oncol       Date:  2015-11-10       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.